An electrospray ionization ion mobility spectrometer (ESI-IMS) is proposed to be used as an innovative process analytical technology (PAT) to overcome the limitations of current cleaning validation systems for pharmaceutical manufacturing and quality assurance. With its sensitivity, speed and portability, IMS has already been used in trace chemical detection that includes cleaning validation applications in pharmaceutical manufacturing processes. However, current commercially available IMS systems have significant limitations in quantitative measurements and in the ability to analyze semi-volatile and non-volatile samples. In this project, an IMS is proposed to be interfaced to a novel electrospray ionization source for on-site analysis of both small molecule and biological pharmaceuticals. The new system will accept samples either directly from a swab or extracted sample solution. As these samples are introduced into the IMS, the targeted analytes are ionized, separated, and quantitatively detected within seconds. More importantly, the new IMS system allows detection of low charge affinity compounds and provides quantitative information of targeted active ingredients and other substance of interests. This on-site analytical technology can significantly reduce manufacturing down time and associated costs in the pharmaceutical manufacturing industry.

Public Health Relevance

The proposed electrospray ionization ion mobility spectrometry (ESI-IMS) based cleaning validation technology is consistent with NIH's Process Analytical Technology (PAT) initiative, the goal of which is to improve efficiency in pharmaceutical manufacturing and quality assurance. This on-site analytical technology can significantly reduce manufacturing down time and associated costs in the pharmaceutical manufacturing industry, and could help lead to lower pharmaceutical costs to the public. Compared to existing IMS based cleaning validation methods, the proposed innovative IMS device fundamentally improves ion mobility spectrometry performance and enables direct introduction of swabbed samples, superior quantitative measurements, and the analysis of non-volatile and biological samples.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44FD003502-02
Application #
7801645
Study Section
Special Emphasis Panel (ZRG1-IMST-G (10))
Program Officer
Needleman, Katherine
Project Start
2009-09-25
Project End
2011-08-31
Budget Start
2009-09-25
Budget End
2010-08-31
Support Year
2
Fiscal Year
2009
Total Cost
Indirect Cost
Name
Excellims Corporation
Department
Type
DUNS #
617297721
City
Acton
State
MA
Country
United States
Zip Code
01720